Proactively manage your pharmacy inventory
Anticipate generic drug launch
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Sustained release indomethacin|
|Abstract:||A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated with a polymer to sustain the plasma level. The uncoated and coated pellets may be mixed with non-medicated pellets as a capsule filler.|
|Inventor(s):||Dempski; Robert E. (Dresher, PA), Mehta; Gunvant N. (Lansdale, PA), Saboe; Joseph C. (Norristown, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
1. A sustained release pharmaceutical formulation in capsule unit dosage form that provides prolonged plasma levels of indomethacin and is clinically effective, containing 25
to 150 mg of 500 to 1500 micron size pellets of indomethacin, in the form of:
(A) Uncoated pellets comprising pharmaceutical carriers and 5-50 mg of indomethacin for immediate release of about 35% of the total indomethacin, and rapid elevation of plasma levels; and
(B) Coated pellets comprising pharmaceutical carriers and 15-145 mg of indomethacin as a sustaining dose of about 65% of the total indomethacin wherein the coating consists of polyvinyl acetate as a slow dissolving material.
2. The pharmaceutical formulation of claim 1, wherein the unit dosage form also includes non-medicated pellets to achieve the correct adjusted fill volume for the capsule.
3. The pharmaceutical formulation of claim 1, wherein component (A) is pellets comprising 10-35% by weight indomethacin; 20-40% by weight confectioner's sugar; 3-15% by weight of hydroxypropylmethylcellulose; 3-15% by weight corn starch; and 15-25% by weight microcrystalline cellulose; and component (B) is component (A) pellets coated with said slow dissolving material.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.